Form 4: Day One Biopharmaceuticals Director Acquires Stock Options

Director Saira Ramasastry acquired stock options in Day One Biopharmaceuticals, Inc. on May 23, 2024.

Summary

• Saira Ramasastry, a director of Day One Biopharmaceuticals, Inc., filed a Form 4 on May 28, 2024, reporting a transaction.
• On May 23, 2024, Ramasastry acquired 32,335 stock options with an exercise price of $13.87.
• The options vest monthly, starting June 23, 2024, over a 12-month period, contingent on continued service to the issuer.
• The options expire on May 22, 2034.
• Following the transaction, Ramasastry directly owns 32,335 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing indicating a director's stock option grant. It doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates